비교리스트

 카트 문의
시장보고서
상품코드
1631234

CGRP 억제제 시장 - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2032년)

CGRP Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032
발행일: | 리서치사: Fairfield Market Research | 페이지 정보: 영문 213 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 CGRP 억제제 시장 규모는 전 세계 편두통 유병률의 증가로 인해 수요가 급증하고 있습니다. CGRP 억제제는 편두통 발병의 핵심인 칼시토닌 유전자 관련 펩타이드(CGRP)를 표적으로 하는 획기적인 의약품으로, CGRP의 활성을 억제하여 편두통의 빈도와 중증도를 현저히 감소시킵니다. 연평균 성장률(CAGR)이 13.90%로 예측되는 이 시장은 상당한 성장세를 보이며 편두통 관리를 재구성하고 전 세계 수백만 명의 삶의 질을 향상시킬 수 있는 효과적인 솔루션을 제공하게 될 것입니다.

CGRP 억제제는 편두통 발병에 중요한 역할을 하는 신경 펩타이드인 칼시토닌 유전자 관련 펩타이드(CGRP)의 활성을 조절하여 작용하며, CGRP가 수용체에 결합하는 것을 차단하거나 방출을 억제함으로써 편두통의 빈도와 편두통의 빈도와 중증도를 유의하게 감소시킵니다. 만성 편두통의 예방 치료제로서 CGRP 억제제는 이 쇠약해진 증상에 대한 치료 분석을 재구성하고 있습니다.

CGRP 억제제 세계 시장은 편두통 치료제의 발전과 환자 및 의료진의 인식 향상에 힘입어 큰 성장을 이룰 것으로 예상됩니다. 시장 참여자들은 혁신적인 솔루션과 전략적 제휴를 통해 효과적인 편두통 치료제에 대한 수요 증가에 대응할 준비를 하고 있습니다. 분석이 발전함에 따라 CGRP 억제제는 편두통 관리의 표준을 재정의하고 전 세계 수백만 명의 사람들에게 희망과 삶의 질 향상을 가져다 줄 것으로 기대됩니다.

전 세계적으로 편두통이 증가함에 따라 표적화된 치료 개입이 필요해지면서 CGRP 억제제에 대한 수요가 증가하고 있으며, CGRP 억제제의 표적 메커니즘은 기존 치료법에 비해 높은 효능과 우수한 안전성 프로파일을 제공함으로써 채택이 증가하고 있습니다. CGRP 억제제의 등장은 편두통 치료의 패러다임이 정밀의료와 맞춤형 의료로 전환되고 있음을 보여줍니다. 의료 서비스 제공자들은 편두통의 예방적 치료가 환자에게 장기적으로 유익하다는 것을 인식하고 진통제 의존도를 낮추기 위해 편두통 예방 치료를 점점 더 많이 지지하고 있습니다. 인식 개선 캠페인과 교육 이니셔티브는 환자들에게 고급 편두통 치료 옵션을 알리는 데 매우 중요한 역할을 하고 있으며, CGRP 억제제에 대한 수요를 더욱 증가시키고 있습니다.

이 보고서는 세계 CGRP 억제제 시장에 대해 조사했으며, 시장 개요와 함께 분자별, 치료별, 투여 경로별, 최종 용도별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등을 조사하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

  • 시장 정의와 세분화
  • 시장 역학
  • 밸류체인 분석
  • Porter's Five Forces 분석
  • COVID-19의 영향 분석
  • 우크라이나·러시아 분쟁의 영향
  • 경제 개요
  • PESTLE 분석

제3장 생산량과 무역 통계, 2019-2023년

제4장 가격 분석, 2019-2023년

제5장 세계의 CGRP 억제제 시장 전망, 2019-2032년

  • 세계의 CGRP 억제제 시장 전망, 분자별, 금액(10억 달러), 수량(100만 개), 2019-2032년
  • 세계의 CGRP 억제제 시장 전망, 치료별, 금액(10억 달러), 수량(100만 개), 2019-2032년
  • 세계의 CGRP 억제제 시장 전망, 투여 경로별, 금액(10억 달러), 수량(100만 개), 2019-2032년
  • 세계의 CGRP 억제제 시장 전망, 최종 용도별, 금액(10억 달러), 수량(100만 개), 2019-2032년
  • 세계의 CGRP 억제제 시장 전망, 지역별, 금액(10억 달러), 수량(100만 개), 2019-2032년

제6장 북미의 CGRP 억제제 시장 전망, 2019-2032년

제7장 유럽의 CGRP 억제제 시장 전망, 2019-2032년

제8장 아시아태평양의 CGRP 억제제 시장 전망, 2019-2032년

제9장 라틴아메리카의 CGRP 억제제 시장 전망, 2019-2032년

제10장 중동 및 아프리카의 CGRP 억제제 시장 전망, 2019-2032년

제11장 경쟁 구도

  • 투여 경로별과 치료별 히트맵
  • 제조업체별과 치료별 히트맵
  • 기업 시장 점유율 분석, 2022년
  • 경쟁 대시보드
  • 기업 개요
    • Amgen
    • Novartis
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly
    • Lundbeck
    • Abbvie
    • Allergan

제12장 부록

ksm 25.01.23

The global CGRP inhibitors market is experiencing a surge in demand due to the rising prevalence of migraines worldwide. These inhibitors, a groundbreaking class of pharmaceuticals, target the calcitonin gene-related peptide (CGRP), a key player in migraine development. By preventing CGRP activity, they significantly reduce the frequency and severity of migraines. With a projected compound annual growth rate (CAGR) of 13.90%, the market is poised to achieve substantial growth, offering targeted and effective solutions that are reshaping migraine management and improving the quality of life for millions globally.

Market Insights

CGRP inhibitors work by modulating the activity of the calcitonin gene-related peptide (CGRP), a neuropeptide that plays a significant role in migraine pathogenesis. By preventing CGRP from binding to its receptors or blocking its release, these inhibitors significantly reduce migraine frequency and severity. As preventive treatments for chronic migraines, CGRP inhibitors are reshaping the therapeutic Analysis for this debilitating condition.

The global CGRP inhibitors market is set to witness significant growth, driven by advancements in migraine therapeutics and increasing awareness among patients and healthcare providers. With innovative solutions and strategic collaborations, the market players are well-positioned to address the growing demand for effective migraine treatments. As the Analysis evolves, CGRP inhibitors continue to redefine the standards of care in migraine management, offering hope and improved quality of life for millions worldwide.

Key Market Drivers

  • Rising Migraine Prevalence: The growing global burden of migraines necessitates targeted therapeutic interventions, driving the demand for CGRP inhibitors.
  • Effectiveness and Precision: The targeted mechanism of CGRP inhibitors offers higher efficacy and better safety profiles compared to traditional treatments, increasing their adoption.
  • Advancements in Migraine Care: The emergence of CGRP inhibitors underscores a paradigm shift in migraine therapeutics, emphasizing precision medicine and personalized care.
  • Shifting Treatment Paradigms: Healthcare providers are increasingly favoring preventive migraine treatments, recognizing their long-term benefits for patients and reducing reliance on pain-relief medications.
  • Growing Awareness Among Patients: Awareness campaigns and educational initiatives have played a pivotal role in informing patients about advanced migraine treatment options, further driving demand for CGRP inhibitors.

Business Opportunities

  • Combination Therapies: Exploring combination treatments involving CGRP inhibitors and other migraine management modalities presents a promising avenue for innovation and revenue growth.
  • Strategic Partnerships: Collaborations between pharmaceutical companies, healthcare institutions, and research organizations can enhance awareness, accessibility, and affordability of CGRP inhibitors.
  • Patient-Centric Solutions: Developing non-invasive and patient-friendly delivery methods, such as nasal sprays, can further expand the market reach.

Regional Analysis

  • Europe: As the leading region, Europe is driving market growth through strategic healthcare initiatives, a robust regulatory framework, and a strong focus on advanced migraine therapies.
  • South Asia & Pacific: This region is the fastest-growing market, supported by a rising migraine burden, increased awareness of innovative treatments, and improved healthcare access.
  • North America: The region's advanced healthcare infrastructure and high adoption rates for innovative therapies position it as a critical market for CGRP inhibitors.

Key Players

Prominent companies in the CGRP inhibitors market include:

  • Amgen
  • Novartis
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly
  • Lundbeck
  • Abbvie
  • Allergan

These organizations are at the forefront of research and development, introducing innovative therapies and expanding their product portfolios to maintain a competitive edge.

Market Segmentation

1. By Molecule:

    Small Molecule Large Molecule

2. By Treatment:

    Preventive Migraine Treatment Acute Migraine Treatment

3. By Route of Administration:

    Oral Nasal Injectables

4. By End-Use:

    Hospitals Specialty Clinics Mail Order Pharmacies Retail Pharmacies

5. By Region:

    North America Europe Asia Pacific Latin America Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global CGRP Inhibitors Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Volume and Value, 2024
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. Covid-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact Of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. Pestle Analysis

3. Production Output and Trade Statistics, 2019 - 2023

  • 3.1. Global CGRP Inhibitors Market Production Output, by Region, Value (US$ Bn) and Volume (Million Units),2019 - 2023
    • 3.1.1. North America
    • 3.1.2. Europe
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. Middle East and Africa

4. Price Analysis, 2019 - 2023

  • 4.1. Global Average Price Analysis, by Type, US$ Per Unit, 2019 - 2023
  • 4.2. Prominent Factor Affecting CGRP Inhibitors Prices
  • 4.3. Global Average Price Analysis, by Region, US$ Per Unit, 2019 - 2023

5. Global CGRP Inhibitors Market Outlook, 2019 - 2032

  • 5.1. Global CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Small Molecule
      • 5.1.1.2. Large Molecule
  • 5.2. Global CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Preventive Migraine Treatment
      • 5.2.1.2. Acute Migraine Treatment
  • 5.3. Global CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Oral
      • 5.3.1.2. Nasal
      • 5.3.1.3. Injectables
  • 5.4. Global CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospitals
      • 5.4.1.2. Specialty Clinics
      • 5.4.1.3. Mail Order Pharmacies
      • 5.4.1.4. Retail Pharmacies
  • 5.5. Global CGRP Inhibitors Market Outlook, by Region, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.5.1. Key Highlights
      • 5.5.1.1. North America
      • 5.5.1.2. Europe
      • 5.5.1.3. Asia Pacific
      • 5.5.1.4. Latin America
      • 5.5.1.5. Middle East & Africa

6. North America CGRP Inhibitors Market Outlook, 2019 - 2032

  • 6.1. North America CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Small Molecule
      • 6.1.1.2. Large Molecule
  • 6.2. North America CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Preventive Migraine Treatment
      • 6.2.1.2. Acute Migraine Treatment
  • 6.3. North America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Oral
      • 6.3.1.2. Nasal
      • 6.3.1.3. Injectables
  • 6.4. North America CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospitals
      • 6.4.1.2. Specialty Clinics
      • 6.4.1.3. Mail Order Pharmacies
      • 6.4.1.4. Retail Pharmacies
  • 6.5. North America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.1. Key Highlights
      • 6.5.1.1. U.S. CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.2. U.S. CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.3. U.S. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.4. U.S. CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.5. Canada CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.6. Canada CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.7. Canada CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.8. Canada CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Europe CGRP Inhibitors Market Outlook, 2019 - 2032

  • 7.1. Europe CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Small Molecule
      • 7.1.1.2. Large Molecule
  • 7.2. Europe CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Preventive Migraine Treatment
      • 7.2.1.2. Acute Migraine Treatment
  • 7.3. Europe CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Oral
      • 7.3.1.2. Nasal
      • 7.3.1.3. Injectables
  • 7.4. Europe CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospitals
      • 7.4.1.2. Specialty Clinics
      • 7.4.1.3. Mail Order Pharmacies
      • 7.4.1.4. Retail Pharmacies
  • 7.5. Europe CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.1. Key Highlights
      • 7.5.1.1. Germany CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.2. Germany CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.3. Germany CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.4. Germany CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.5. U.K. CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.6. U.K. CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.7. U.K. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.8. U.K. CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.9. France CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.10. France CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.11. France CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.12. France CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.13. Italy CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.14. Italy CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.15. Italy CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.16. Italy CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.17. Turkey CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.18. Turkey CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.19. Turkey CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.20. Turkey CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.21. Russia CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.22. Russia CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.23. Russia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.24. Russia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.25. Rest Of Europe CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.26. Rest Of Europe CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.27. Rest Of Europe CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.28. Rest of Europe CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific CGRP Inhibitors Market Outlook, 2019 - 2032

  • 8.1. Asia Pacific CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Small Molecule
      • 8.1.1.2. Large Molecule
  • 8.2. Asia Pacific CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Preventive Migraine Treatment
      • 8.2.1.2. Acute Migraine Treatment
  • 8.3. Asia Pacific CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Oral
      • 8.3.1.2. Nasal
      • 8.3.1.3. Injectables
  • 8.4. Asia Pacific CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospitals
      • 8.4.1.2. Specialty Clinics
      • 8.4.1.3. Mail Order Pharmacies
      • 8.4.1.4. Retail Pharmacies
  • 8.5. Asia Pacific CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.1. Key Highlights
      • 8.5.1.1. China CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.2. China CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.3. China CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.4. China CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.5. Japan CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.6. Japan CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.7. Japan CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.8. Japan CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.9. South Korea CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.10. South Korea CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.11. South Korea CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.12. South Korea CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.13. India CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.14. India CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.15. India CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.16. India CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.17. Southeast Asia CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.18. Southeast Asia CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.19. Southeast Asia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.20. Southeast Asia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.21. Rest Of Asia Pacific CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.22. Rest Of Asia Pacific CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.23. Rest Of Asia Pacific CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.24. Rest of Asia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America CGRP Inhibitors Market Outlook, 2019 - 2032

  • 9.1. Latin America CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.1.1. Key Highlights
      • 9.1.1.1. Small Molecule
      • 9.1.1.2. Large Molecule
  • 9.2. Latin America CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.2.1. Key Highlights
      • 9.2.1.1. Preventive Migraine Treatment
      • 9.2.1.2. Acute Migraine Treatment
  • 9.3. Latin America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.3.1. Key Highlights
      • 9.3.1.1. Oral
      • 9.3.1.2. Nasal
      • 9.3.1.3. Injectables
  • 9.4. Latin America CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.4.1. Key Highlights
      • 9.4.1.1. Hospitals
      • 9.4.1.2. Specialty Clinics
      • 9.4.1.3. Mail Order Pharmacies
      • 9.4.1.4. Retail Pharmacies
  • 9.5. Latin America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.1. Key Highlights
      • 9.5.1.1. Brazil CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.2. Brazil CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.3. Brazil CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.4. Brazil CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.5. Mexico CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.6. Mexico CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.7. Mexico CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.8. Mexico CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.9. Argentina CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.10. Argentina CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.11. Argentina CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.12. Argentina CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.13. Rest Of Latin America CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.14. Rest Of Latin America CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.15. Rest Of Latin America CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.16. Rest of Latin America CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa CGRP Inhibitors Market Outlook, 2019 - 2032

  • 10.1. Middle East & Africa CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.1.1. Key Highlights
      • 10.1.1.1. Small Molecule
      • 10.1.1.2. Large Molecule
  • 10.2. Middle East & Africa CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.2.1. Key Highlights
      • 10.2.1.1. Preventive Migraine Treatment
      • 10.2.1.2. Acute Migraine Treatment
  • 10.3. Middle East & Africa CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.3.1. Key Highlights
      • 10.3.1.1. Oral
      • 10.3.1.2. Nasal
      • 10.3.1.3. Injectables
  • 10.4. Middle East & Africa CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.4.1. Key Highlights
      • 10.4.1.1. Hospitals
      • 10.4.1.2. Specialty Clinics
      • 10.4.1.3. Mail Order Pharmacies
      • 10.4.1.4. Retail Pharmacies
  • 10.5. Middle East & Africa CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.5.1. Key Highlights
      • 10.5.1.1. GCC CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.2. GCC CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.3. GCC CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.4. GCC CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.5. South Africa CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.6. South Africa CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.7. South Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.8. South Africa CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.9. Egypt CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.10. Egypt CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.11. Egypt CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.12. Egypt CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.13. Nigeria CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.14. Nigeria CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.15. Nigeria CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.16. Nigeria CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.17. Rest Of Middle East & Africa CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.18. Rest Of Middle East & Africa CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.19. Rest Of Middle East & Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.20. Rest of Middle East & Africa CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.5.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

  • 11.1. By Route of Administration Vs by Treatment Heat Map
  • 11.2. Manufacturer Vs by Treatment Heatmap
  • 11.3. Company Market Share Analysis, 2022
  • 11.4. Competitive Dashboard
  • 11.5. Company Profiles
    • 11.5.1. Amgen
      • 11.5.1.1. Company Overview
      • 11.5.1.2. Type Portfolio
      • 11.5.1.3. Financial Overview
      • 11.5.1.4. Business Strategies and Development
    • 11.5.2. Novartis
      • 11.5.2.1. Company Overview
      • 11.5.2.2. Type Portfolio
      • 11.5.2.3. Financial Overview
      • 11.5.2.4. Business Strategies and Development
    • 11.5.3. Teva Pharmaceutical Industries Ltd.
      • 11.5.3.1. Company Overview
      • 11.5.3.2. Type Portfolio
      • 11.5.3.3. Financial Overview
      • 11.5.3.4. Business Strategies and Development
    • 11.5.4. Eli Lilly
      • 11.5.4.1. Company Overview
      • 11.5.4.2. Type Portfolio
      • 11.5.4.3. Financial Overview
      • 11.5.4.4. Business Strategies and Development
    • 11.5.5. Lundbeck
      • 11.5.5.1. Company Overview
      • 11.5.5.2. Type Portfolio
      • 11.5.5.3. Financial Overview
      • 11.5.5.4. Business Strategies and Development
    • 11.5.6. Abbvie
      • 11.5.6.1. Company Overview
      • 11.5.6.2. Type Portfolio
      • 11.5.6.3. Financial Overview
      • 11.5.6.4. Business Strategies and Development
    • 11.5.7. Allergan
      • 11.5.7.1. Company Overview
      • 11.5.7.2. Type Portfolio
      • 11.5.7.3. Financial Overview
      • 11.5.7.4. Business Strategies and Development

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Report Assumptions
  • 12.3. Acronyms And Abbreviations
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제